Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo do PHST001 em tumores sólidos avançados

30 de setembro de 2026 atualizado por: Pheast Therapeutics

Um estudo aberto, Fase 1A/1B, escalada de doses e estudo de expansão da dose que investiga a atividade de segurança, farmacocinética, farmacodinâmica e antitumoral de PHST001 em pacientes adultos com tumores sólidos recidivados e/ou refratários avançados e/ou refratários

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.

The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

426

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Raphaël Rousseau, Chief Medical Officer, PhD, MD
  • Número de telefone: 650-260-8443
  • E-mail: medical@pheast.com

Locais de estudo

    • California
      • Beverly Hills, California, Estados Unidos, 90212
      • Los Angeles, California, Estados Unidos, 90033
      • Palo Alto, California, Estados Unidos, 94304
        • Recrutamento
        • Stanford University School of Medicine
        • Contato:
        • Investigador principal:
          • Oliver Dorigo, MD, PhD
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Recrutamento
        • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
        • Contato:
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Recrutamento
        • Yale Cancer Center
        • Investigador principal:
          • Michael Cecchini, MD
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan Rogel Cancer Center
        • Investigador principal:
          • Ulka Vaishampayan, MD
        • Contato:
      • Grand Rapids, Michigan, Estados Unidos, 49546
        • Recrutamento
        • START Center for Cancer Research - Midwest
        • Investigador principal:
          • Sreenivasa Chandana, MD, PhD
        • Contato:
    • New York
      • Lake Success, New York, Estados Unidos, 11042
        • Recrutamento
        • START Center for Cancer Research - Long Island New York
        • Investigador principal:
          • Geraldine O'Sullivan Coyne, MD
        • Contato:
      • New York, New York, Estados Unidos, 10029
        • Recrutamento
        • Mount Sinai
        • Investigador principal:
          • Thomas Marron, MD, PhD
        • Contato:
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Recrutamento
        • Duke Cancer Institute
        • Contato:
        • Investigador principal:
          • Niharika Mettu, MD, PhD
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • Vanderbilt-Ingram Cancer Center
        • Contato:
          • Clinical Trials Office (CTO)
          • Número de telefone: 1-800-811-8480
          • E-mail: cip@vumc.org
        • Investigador principal:
          • Elizabeth Davis, MD, PhD
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • Sarah Cannon Research Institute (SCRI) Oncology Partners
        • Investigador principal:
          • Deepak Bhamidipati, MD
        • Contato:
          • SCRI Oncology Partners - Nashville
          • Número de telefone: 1-877-MY-1-SCRI (691-7274)
          • E-mail: ASKSARAH@scresearch.net
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Recrutamento
        • START Center for Cancer Research - Texas
        • Contato:
        • Investigador principal:
          • Henry Xiong, MD, PhD
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • MD Anderson Cancer Center
        • Contato:
        • Investigador principal:
          • Stéphane Champiat, MD, PhD
      • Irving, Texas, Estados Unidos, 75039
        • Recrutamento
        • NEXT Oncology - Dallas
        • Investigador principal:
          • Michael Song, MD, PhD, PharmD
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • University of Texas (UT) Health
        • Investigador principal:
          • Daruka Mahadevan, MD, PhD
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • START Center for Cancer Research - San Antonio
        • Investigador principal:
          • Kyriakos Papadopoulos, MD
        • Contato:
    • Virginia

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

  • Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
  • Adequate organ function per laboratory testing
  • Pregnancy prevention requirements
  • Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
  • Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale

Key Exclusion Criteria:

  • Diagnosis of immunodeficiency
  • History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
  • Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
  • Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
  • Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
  • Received previous treatment with another agent targeting CD24.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: PHST001 Monotherapy

Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Experimental: PHST001 + Paclitaxel

Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Paclitaxel used as per standard of care.

Outros nomes:
  • Taxol
Experimental: PHST001 + Topotecan

Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Topotecan used as per standard of care.

Outros nomes:
  • Hycamtin
Experimental: PHST001 + Doxorubicin

Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Doxorubicin used as per standard of care.

Outros nomes:
  • Adriamicina
Experimental: PHST001 + FOLFIRI

Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

FOLFIRI used as per standard of care.

Outros nomes:
  • folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan combination
Experimental: PHST001 + FOLFOX

Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

FOLFOX used as per standard of care.

Outros nomes:
  • folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin combination
Experimental: PHST001 + Gemcitabine

Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Gemcitabine used as per standard of care.

Outros nomes:
  • Gemzar
Experimental: PHST001 + Mirvetuximab Soravtansine

Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Mirvetuximab soravtansine used as per standard of care.

Outros nomes:
  • MIRV, Elahere
Experimental: PHST001 + Trastuzumab Deruxtecan

Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Trastuzumab deruxtecan used as per standard of care.

Outros nomes:
  • T-DXd, Enhertu
Comparador Ativo: Mirvetuximab Soravtansine Monotherapy

Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy.

Mirvetuximab soravtansine used as per standard of care.

Outros nomes:
  • MIRV, Elahere

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From first dose of PHST001 through 21 days after the first dose of PHST001

Based on toxicities observed

From first dose of PHST001 through 21 days after the first dose of PHST001
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From signed consent up to 90 days after the last dose of PHST001

Based on toxicities observed

From signed consent up to 90 days after the last dose of PHST001
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
Prazo: From screening and during treatment up to 2 years

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
Prazo: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

From screening and during treatment up to 2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
Prazo: From screening and during treatment up to 2 years

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

From screening and during treatment up to 2 years
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Prazo: From screening and during treatment up to 2 years

Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.

From screening and during treatment up to 2 years
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Prazo: From screening and during treatment up to 2 years

Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment.

From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
Prazo: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

From screening and during treatment up to 2 years
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
Prazo: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to the date of death.

From screening and during treatment up to 2 years
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
Prazo: From treatment until 90 days after last dose of PHST001

Defined as the maximum blood concentration of a dose of PHST001

From treatment until 90 days after last dose of PHST001
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From treatment until 90 days after last dose of PHST001

Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration.

From treatment until 90 days after last dose of PHST001
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From treatment until 90 days after last dose of PHST001

Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration).

From treatment until 90 days after last dose of PHST001
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From treatment until 90 days after last dose of PHST001

Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile.

From treatment until 90 days after last dose of PHST001
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From treatment until 90 days after last dose of PHST001

Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered.

From treatment until 90 days after last dose of PHST001
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From treatment until 90 days after last dose of PHST001

Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream.

From treatment until 90 days after last dose of PHST001
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Prazo: From treatment until 90 days after last dose of PHST001

Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination.

From treatment until 90 days after last dose of PHST001

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de março de 2025

Conclusão Primária (Estimado)

1 de abril de 2029

Conclusão do estudo (Estimado)

1 de abril de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

10 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de fevereiro de 2025

Primeira postagem (Real)

21 de fevereiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • PHST001-101

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever